Petros Pharmaceuticals Provides Letter To Shareholders; Developing and executing on a new pathway toward non-prescription for lead product; Outlines Milestones For STENDRA
Portfolio Pulse from Benzinga Newsdesk
Petros Pharmaceuticals is shifting its focus from commercializing prescription STENDRA to developing a non-prescription or over-the-counter access for the product. The company is using new FDA rules to bring mature Rx products to the market without a prescription. Petros is also exploring potential partnerships to develop technology for safety and is gathering a team to ensure compliance with FDA regulations.
September 11, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Petros Pharmaceuticals' shift to non-prescription access for STENDRA and the exploration of potential partnerships for technology development could potentially increase the company's market reach and revenue.
The shift to non-prescription access for STENDRA could potentially increase the product's market reach and sales, positively impacting Petros Pharmaceuticals' revenue. The exploration of potential partnerships for technology development could also provide additional revenue streams and strengthen the company's market position.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100